Anemia treatment of lymphoproliferative malignancies with erypoiesis: an overview of state of the art.
Study Goal
The researchers aimed to evaluate the safety, efficacy, and impact of Erythropoiesis-Stimulating Agents (ESAs) on hemoglobin response, quality of life, and adverse events in patients with lymphoproliferative malignancies, particularly multiple myeloma.
Results Summary
The study found that ESAs were safe and effective, with 69.1% of patients achieving a hemoglobin response (>2g/dl increase). Iron supplementation improved response rates and reduced costs, while HYPO% was a significant predictor for hemoglobin response and iron need.
Population
Patients with lymphoproliferative malignancies, especially multiple myeloma.
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
ESAs (erythropoiesis stimulating agents) | no change | mortality or serious adverse events | patients with lymphoproliferative malignancies, especially multiple myeloma | no significant change | safe and effective and not associated with an increase | #1 |
ESAs (erythropoiesis stimulating agents) | increase | hemoglobin | patients | 69.1% | achieved a hemoglobin response | #2 |
ESAs (erythropoiesis stimulating agents) | increase | hemoglobin | patients | >2g/dl | increase in hemoglobin | #3 |
iron supplementation | increase | hemoglobin response rate | patients receiving ESAs and concomitant chemotherapy | - | increased | #4 |
iron supplementation | decrease | total dosage and financial cost | patients receiving ESAs and concomitant chemotherapy | - | reduced | #5 |
hemoglobin response | increase | quality of life | patients | - | accompanied by an increase | #6 |
HYPO% (hypochromic erythrocytes<5%) | neutral | Hb response | - | - | significant positive predictor | #7 |
HYPO% (hypochromic erythrocytes<5%) | neutral | iron supplementation | - | ⩾5% | indicator for iron supplementation | #8 |
serum ferritin concentration and transferrin saturation | neutral | predictor for Hb response or indicator for iron supplementation | - | - | not reliable | #9 |
Anemia is a common comorbidity of lymphoproliferative malignancies, especially in multiple myeloma. Blood transfusions and ESAs (erythropoiesis stimulating agents) are both possible treatment options, but the latter is often preferred because of the potential risks of unwanted side effects related to blood transfusions. Evidence is accumulating that the use of ESAs in above clinical conditions is safe and effective and not associated with an increase in mortality or serious adverse events. 69.1% of patients achieved a hemoglobin response defined as an increase in hemoglobin of>2g/dl while receiving ESAs and concomitant chemotherapy. If supplemented with iron the hemoglobin response rate can be increased and hence the total dosage and financial cost reduced. A hemoglobin response is often accompanied by an increase in quality of life. HYPO% (hypochromic erythrocytes<5%) is believed to be both a significant positive predictor for the Hb response and also an indicator for iron supplementation if⩾5%. Conventional biochemical markers like serum ferritin concentration and transferrin saturation are not reliable for this use. The effect of EPO stimulating agents as the predictor of the Hb response, quality of life, mortality and the potential adverse events are discussed.